Patient-led experimentation is increasingly influencing //conversations around cancer treatment options * ClinicalTrials are urgently needed before fenbendazole can be considere ...
The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
The current melanoma staging system does not always reflect actual survival outcomes. In some cases, patients with thick but ...
A preliminary study found that people receiving immunotherapy for lung cancer or melanoma lived longer if they had received ...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or ...
New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
Iovance Biotherapeutics ($IOVA) announced an update on their ongoing clinical study. Iovance Biotherapeutics has provided an update on its Phase 2 ...
Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 ...
The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...
Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...
Please provide your email address to receive an email when new articles are posted on . The PFS benefit from adding a vaccine to pembrolizumab narrowly missed the statistical significance threshold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback